Analysts Are Bullish on Top Healthcare Stocks: Concentra Group Holdings Parent, Inc. (CON), Neurocrine (NBIX)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Concentra Group Holdings Parent, Inc. (CON – Research Report) and Neurocrine (NBIX – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Concentra Group Holdings Parent, Inc. (CON)
In a report released today, Joanna Gajuk from Bank of America Securities reiterated a Buy rating on Concentra Group Holdings Parent, Inc., with a price target of $27.00. The company’s shares closed last Wednesday at $21.48.
According to TipRanks.com, Gajuk is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Concentra Group Holdings Parent, Inc. with a $27.33 average price target, which is a 26.5% upside from current levels. In a report released today, TipRanks – Google also upgraded the stock to Buy with a $24.50 price target.
See Insiders’ Hot Stocks on TipRanks >>
Neurocrine (NBIX)
Citi analyst Yigal Nochomovitz maintained a Buy rating on Neurocrine yesterday and set a price target of $203.00. The company’s shares closed last Wednesday at $134.66.
According to TipRanks.com, Nochomovitz is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Neurocrine with a $182.06 average price target, a 36.9% upside from current levels. In a report issued on January 15, TipRanks – xAI also upgraded the stock to Buy with a $149.00 price target.
